Industry News

GSK Consumer Healthcare is voluntarily recalling five lots (listed below) of Benefiber Healthy Shape Prebiotic Fiber Supplement powder and Benefiber Prebiotic Fiber Supplement powder due to the potential for green plastic pieces or shavings from bottle caps to be present in the product. There is a potential risk of choking or physical injury to the soft tissues of the mouth or gastrointestinal tract of a consumer using the product who may not see a broken piece or shaving of plastic cap.

Glenmark  Pharmaceuticals  Inc.,  USA  (Glenmark)  has  been  granted tentativeapproval by the United States Food & Drug Administration (U.S. FDA) for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg, the generic version of Qtern®1Tablets, 10 mg/5 mg, of AstraZeneca AB.

In a major step to make India self-reliant in COVID-19 testing, Mylab Discovery Solutions, a Pune based molecular diagnostics has collaborated with Kiran Mazumdar Shaw’s Syngene, a leading global contract research organization, to cater to India’s demand for RT-PCR COVID-19 testing kits.

Despite the COVID-19 crisis, the Indian Pharmaceutical market registered a surprising growth of 8.9% in Mar’20 with some evidence of panic buying in Chronic Medicines as reported by AIOCD AWACS.

Cipla Limited announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (US FDA).

In September 2019, The USFDA has observed that, some ranitidine medicines contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. SMS Pharma is one of the manufacturer of Ranitidine HCl Active Pharmaceuticals Ingredient (API).

Pharma major Lupin Limited (Lupin) announced a contribution of INR 21 crores for relief efforts directed towards mitigating the COVID-19 crisis. Lupin’s Global Giving Program comprises of three separate contributions made by its employees, the Company and the promoter family.

BioNTech SE and Pfizer Inc disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.

The U.S. Food and Drug Administration issued an emergency use authorization for a blood purification system to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.